Following on from information provided to NICE by the company in February 2022, the appraisal of Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 3781

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 February 2023 Discontinued. Following on from information provided to NICE by the company in February 2022, the appraisal of Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
01 February 2022 Suspended. For information, the company have announced that TRYbeCA-1 Phase 3 Trial did not meet its primary endpoint in Eryaspase in patients with second-line advanced pancreatic cancer and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes
01 April 2020 Topic has been referred

For further information on our processes and methods, please see our CHTE processes and methods manual